July 2022

Everads Therapy announced today that Israel’s Innovation Authority (IIA) has awarded a grant to help fund the company’s research and development. Moshe Weinstein, Everads’ CEO, stated that “We are excited to have been awarded this competitive grant, the receipt of which is a validation of the strong business and scientific case for our technology and pipeline. The grant programs of the Israel Innovation Authority are a true catalyst for Israeli companies, and we are honored and humbled to have been chosen.”


August 2020

Global Pharma Company Exercises Rights for Exclusive Use of Everads Drug Delivery Technology in Specific Retinal Targets.

While granting the pharma company exclusivity for specific ocular targets, Everads has retained the right to work on other targets and treatments, both independently and with other partners.


March 2022

Ophthalmology Times: "Suprachoroidal delivery system gets drug to the macula, posterior segment"

צילום מסך 2022-07-08 ב-15.18.28.png

July 2020

Everads Therapy featured on European Union's CORDIS website:
The European Union has selected Everads for a publication in the ‘Results in Brief’ section of the European Commission’s CORDIS website.​


June  2021​

Everads Enters into Collaboration to Evaluate its Suprachoroidal Delivery Technology with a Clinical-Stage Gene Therapy Company

-  Under new collaboration, partner given opt-in right to license specific retinal targets in exchange for pre-agreed license fees, development milestones and royalties

-  Agreement follows a previously-announced option deal with a global pharmaceutical company evaluating Everads' technology

Senior Woman

March 2020

Everads Therapy Enters Into Option Agreement With Global Pharma Company to License Everads' Suprachoroidal Delivery System for Retinal Disease Therapies;

- Agreement Supports Potential of Everads' Novel Technology and Method for Delivery of Posterior Segment Therapeutics to the Suprachoroidal Space.

Senior Portrait